Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2020

Braunstein MJ, Petrova-Drus K, Rosenbaum CA, Jayabalan DS, Rossi AC, Salvatore S, et al. Plasma Cell Myeloma Presenting With Amyloid-Laden Crystal-Negative Histiocytosis. Am J Clin Pathol. 2020;154(6):767-775.

Fujiyoshi K, Väyrynen JP, Borowsky J, Papke DJ, Arima K, Haruki K, et al. Tumour budding, poorly differentiated clusters, and T-cell response in colorectal cancer. EBioMedicine. 2020;57:102860.

Cheleuitte-Nieves C, Heselpoth RD, Westblade LF, Lipman NS, Fischetti VA. Searching for a Bacteriophage Lysin to Treat in Immunocompromised Mice. Comp Med. 2020;70(4):328-335.

Lopez A, Trager MH, Magro C, Geskin LJ. Collisional variant of CD8 mycosis fungoides and indolent CD8 lymphoid proliferation. JAAD Case Rep. 2020;6(9):921-924.

Vosoughi A, Zhang T, Shohdy KS, Vlachostergios PJ, Wilkes DC, Bhinder B, et al. Common germline-somatic variant interactions in advanced urothelial cancer. Nat Commun. 2020;11(1):6195.

Goel S, Shoag JE, Gross MD, Awamlh BA, Robinson B, Khani F, et al. Concordance Between Biopsy and Radical Prostatectomy Pathology in the Era of Targeted Biopsy: A Systematic Review and Meta-analysis. Eur Urol Oncol. 2020;3(1):10-20.

Casiraghi N, Orlando F, Ciani Y, Xiang J, Sboner A, Elemento O, et al. ABEMUS: platform-specific and data-informed detection of somatic SNVs in cfDNA. Bioinformatics. 2020;36(9):2665-2674.

Chung EY, McIlroy K, Fung C, Seshan SV, Moran S, Coleman PL. Glomerular, Mesangial, and Tubular Cytoplasmic Fibrillary Inclusions in a Patient with Light-Chain Proximal Tubulopathy. Nephron. 2020;144(4):190-194.

Xu B, Barbieri AL, Bishop JA, Chiosea SI, Dogan S, Di Palma S, et al. Histologic Classification and Molecular Signature of Polymorphous Adenocarcinoma (PAC) and Cribriform Adenocarcinoma of Salivary Gland (CASG): An International Interobserver Study. Am J Surg Pathol. 2020;44(4):545-552.

Schatz-Siemers N, Chen Y-, Chen Z, Wang D, Ellenson LH, Du Y-. Expression of the Receptor for Hyaluronic Acid-Mediated Motility (RHAMM) in Endometrial Cancer is Associated With Adverse Histologic Parameters and Tumor Progression. Appl Immunohistochem Mol Morphol. 2020;28(6):453-459.